🇺🇸 FDA

Company profile · Sponsor

ONCOLYTICS

ONCOLYTICS BIOTECH INC

ONCY · NYSE biotech SAN DIEGO, CA, USA
Pipeline
23
Drugs
0
Patents
8

Quick answer

ONCOLYTICS (ONCY) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ONCY
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0001129928

Pipeline (23)

Search pipeline →

  1. REOLYSIN

    ONCOLYTICS

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

  2. Bevacizumab

    ONCOLYTICS

    Ras-mutated Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  3. Docetaxel, Reolysin and Prednisone

    ONCOLYTICS

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  4. Folfox plus Bevacizumab and reolysin

    ONCOLYTICS

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. Paclitaxel

    ONCOLYTICS

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. Paclitaxel

    ONCOLYTICS

    Breast Cancer Metastatic

    phase 2 small molecule active

    1 trial

  7. Pelareorep

    ONCOLYTICS

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  8. Pelareorep

    ONCOLYTICS

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  9. Pemetrexed and Reolysin (and safety run-in)

    ONCOLYTICS

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  10. REOLYSIN

    ONCOLYTICS

    Metastatic Melanoma

    phase 2 mab completed

    1 trial

  11. REOLYSIN

    ONCOLYTICS

    Metastatic Pancreatic Adenocarcinoma

    phase 2 mab completed

    1 trial

  12. REOLYSIN

    ONCOLYTICS

    Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

    phase 2 mab completed

    1 trial

  13. REOLYSIN®

    ONCOLYTICS

    Carcinoma, Non-small Cell Lung

    phase 2 mab completed

    1 trial

  14. REOLYSIN®

    ONCOLYTICS

    Osteosarcoma

    phase 2 mab completed

    1 trial

  15. pelareorep, Tecentriq 840 mg concentrate for solution for infusion

    ONCOLYTICS

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  16. Bortezomib

    ONCOLYTICS

    Recurrent Plasma Cell Myeloma

    phase 1 small molecule completed

    1 trial

  17. Carfilzomib

    ONCOLYTICS

    Recurrent Plasma Cell Myeloma

    phase 1 small molecule completed

    1 trial

  18. Lenalidomide or Pomalidomide

    ONCOLYTICS

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  19. Pelareorep

    ONCOLYTICS

    Breast Cancer

    phase 1 mab terminated

    1 trial

  20. REOLYSIN®

    ONCOLYTICS

    Malignant Glioma

    phase 1 mab completed

    1 trial

  21. REOLYSIN®

    ONCOLYTICS

    Muscle-invasive Transitional Cell Carcinoma of the Bladder

    phase 1 mab terminated

    1 trial

  22. REOLYSIN®

    ONCOLYTICS

    KRAS Mutant Metastatic Colorectal Cancer

    phase 1 mab completed

    1 trial

  23. REOLYSIN®

    ONCOLYTICS

    Pancreatic Adenocarcinoma

    phase 1 mab completed

    1 trial

Patents (8)

Search patents →

  1. US 11542526

    Oncolytic adenoviral vector and methods of use

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11246930

    Reoviruses having modified sequences

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10596260

    Reoviruses having modified sequences

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10167452

    Viral purification methods

    Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10039827

    Reoviruses having modified sequences

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9610309

    Liquid viral formulations

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9610352

    Lyophilized viral formulations

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9365823

    Virus clearance of neoplastic cells from mixed cellular compositions

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ONCOLYTICS?

ONCOLYTICS (ONCY) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does ONCOLYTICS sponsor?

We track 23 ClinicalTrials.gov-linked programs for ONCOLYTICS, including REOLYSIN and 22 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does ONCOLYTICS company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.